1-(叔丁基二甲基硅基)-3-氯丙烷 | 89031-82-3

• 物质功能分类: 化学试剂 - 硅烷试剂
• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 中文名称: 1-(叔丁基二甲基硅基)-3-氯丙烷
• 中文别名: 1-(叔丁基二甲基硅氧基)-3-氯丙烷
• 英文名称: tert-butyl(3-chloropropoxy)dimethylsilane
• 英文别名: 1-(t-Butyldimethylsilyloxy)-3-chloro-propane；tert-butyl-(3-chloropropoxy)-dimethylsilane
• CAS: 89031-82-3
• 化学式: C₉H₂₁ClOSi
• mdl: MFCD09909983
• 分子量: 208.804
• InChiKey: LROUBCOBLAPPAT-UHFFFAOYSA-N

物化性质

• 沸点：
  198.3±13.0 °C(Predicted)
• 密度：
  0.899
• 闪点：
  >65℃

计算性质

• 辛醇/水分配系数(LogP)：
  3.05
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 安全说明：
  S24,S26,S28
• 危险类别码：
  R36/37/38
• 海关编码：
  2931900090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  存储条件：2~8℃，干燥，密封。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: tert-Butyl(3-chloropropoxy)dimethylsilane
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: tert-Butyl(3-chloropropoxy)dimethylsilane
CAS number: 89031-82-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H21ClOSi
Molecular weight: 208.8

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途：1-(叔丁基二甲基硅基)-3-氯丙烷广泛应用于有机合成和医药中间体等领域。

反应信息

• 作为反应物：
  描述：

  1-(叔丁基二甲基硅基)-3-氯丙烷 在 正丁基锂 、 PdCl2(dppf)*CHCl3 、 sodium hexamethyldisilazane 、 caesium carbonate 、 六甲基二硅氮烷 、 sodium iodide 、 potassium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 106.05h， 生成 2-[(7S)-7-[3-[tert-butyl(dimethyl)silyl]oxypropyl]-6-oxo-7-(2-phenylmethoxyethyl)pyrido[1,2-a]indol-10-yl]ethyl acetate
  参考文献：
  名称：

  Total Synthesis of (−)-Goniomitine

  摘要：

  The total synthesis of (-)-goniomitine has been accomplished in 11 steps starting from commercially available diethyl l-malate. The synthesis features a chiral pool approach to prepare the chiral C-9 unit containing a quaternary carbon center, an Ir-catalyzed C-H borylation to synthesize the 2-indoleboronic acid pinacol ester, and a Suzuki reaction to couple together the two key intermediates. Notably, the high degree of convergence of this strategy makes it particularly amenable to the total synthesis of other aspidosperma family natural products.

  DOI：

  10.1021/ol501341b
• 作为产物：
  描述：

  叔丁基二甲基氯硅烷 、 3-氯-1-丙醇 在 咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 以95%的产率得到1-(叔丁基二甲基硅基)-3-氯丙烷
  参考文献：
  名称：

  构象受限的法呢基转移酶的5,6,7,8-四氢咪唑并[1,5-a]吡啶抑制剂的合成。

  摘要：

  [反应：见正文]通过胺和亚胺的缩合反应生成的亚胺离子的分子内环化反应完成了8-氨基-5,6,7,8-四氢咪唑并[1,5-a]吡啶环系统的合成。取代的γ-（1-咪唑基）丁醛。该反应用于产生构象受限的法尼基转移酶抑制剂类似物，其表现出改善的体内代谢稳定性。

  DOI：

  10.1021/ol0002424

文献信息

• Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors
  作者：Xiaoqi Liu、Yuanyuan Hu、Anhui Gao、Meng Xu、Lixin Gao、Lei Xu、Yubo Zhou、Jianrong Gao、Qing Ye、Jia Li

  DOI：10.1016/j.bmc.2018.12.029

  日期：2019.2

  A series of 3-aryl-4-indolylmaleimide IDH1/R132H inhibitors with a novel structure was obtained by high-throughput screening and structure-based optimization. Most compounds such as 7a, 7d, 7h, 7i, 7k and 7o showed high inhibitory effects on IDH1/R132H and were highly selective against IDH1/WT, IDH2/WT, GDH, GK, and FBP. Evaluation of the biological activities and function at cellular level showed

  通过高通量筛选和基于结构的优化，获得了一系列具有新颖结构的3-芳基-4-吲哚基马来酰亚胺IDH1 / R132H抑制剂。大多数化合物（例如7a，7d，7h，7i，7k和7o）对IDH1 / R132H表现出高抑制作用，并且对IDH1 / WT，IDH2 / WT，GDH，GK和FBP具有高度选择性。在细胞水平上对生物学活性和功能的评价表明，化合物7h，7i和7k可以有效抑制表达IDH1 / R132H的U87MG细胞中2-羟基戊二酸的产生。此外，IDH1 / R132H的过表达可能会导致7h逆转髓样白血病细胞系TF-1的分化阻滞。我们还根据实验数据探索了结构-活性关系，以期为将来的研究铺平道路。
• [EN] IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST<br/>[FR] DÉRIVÉS D'IMIDAZO[2,1-F] [1, 2, 4] TRIAZIN-4-AMINE UTILISÉS EN TANT QU'AGONISTES DE TLR7
  申请人：BEIGENE LTD

  公开号：WO2020160711A1

  公开（公告）日：2020-08-13

  Disclosed herein is an imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as a TLR7 agonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as TLR7 agonist.

  披露的是一种咪唑[2,1-f][1,2,4]三嗪-4-胺衍生物或其立体异构体，或其药用可接受盐，用作TLR7激动剂，以及包含该化合物的药物组合物。还披露了一种使用咪唑[2,1-f][1,2,4]三嗪-4-胺衍生物或其立体异构体，或其药用可接受盐作为TLR7激动剂来治疗癌症的方法。
• [EN] FGFR4 INHIBITORS<br/>[FR] INHIBITEURS DE FGFR4
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2016164754A1

  公开（公告）日：2016-10-13

  We provide FGFR inhibitors, their salts, methods of manufacture, and methods of use.

  我们提供FGFR抑制剂，它们的盐，制造方法和使用方法。
• HISTONE DEMETHYLASE INHIBITORS
  申请人：Quanticel Pharmaceuticals, Inc.

  公开号：US20140171432A1

  公开（公告）日：2014-06-19

  The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted 3-aminopyridine derivative compounds, substituted 3-aminopyridazine derivative compounds, and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本发明一般涉及治疗癌症和肿瘤性疾病的组合物和方法。本文提供了替代的3-氨基吡啶衍生物化合物，替代的3-氨基吡啶嗪衍生物化合物，以及包含所述化合物的药物组合物。所述化合物和组合物对于抑制组蛋白去甲基化酶是有用的。此外，所述化合物和组合物对于治疗癌症，如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等是有用的。
• Total Synthesis of the Calphostins:  Application of Fischer Carbene Complexes and Thermodynamic Control of Atropisomers
  作者：Craig A. Merlic、Courtney C. Aldrich、Jennifer Albaneze-Walker、Alan Saghatelian、Jerome Mammen

  DOI：10.1021/jo0014663

  日期：2001.2.1

  perylenequinones. Thermal equilibration to a 3:1 P:M atropisomeric ratio and separation of the perylenequinones followed by side chain desymmetrization and functionalization led to the total synthesis of enantio- and diastereomerically pure calphostin C in only twelve steps from commercially available starting materials. In addition, calphostins A, B, D, and several structural analogues were prepared to evaluate

  据报道有效的蛋白激酶C抑制剂钙磷蛋白A，B，C和D以及各种结构类似物的总合成。利用对映纯菲舍尔卡宾络合物的氨基苯甲酸酯化反应制备五取代的萘胺。优化侧链取代基后，将萘胺转化为邻萘醌，然后使用三氟乙酸和空气进行仿生氧化二聚，得到阻转异构体per醌的1：2 P / M混合物。热平衡至3：1 P：M的对映异构体比例，并分离出ylene醌，然后进行侧链去对称和官能化，仅用十二个步骤就可以从市售起始原料完全合成对映体和非对映体纯钙黄素C。此外，